Kornimate/medical-research-clean huggingface dataset:
observational study of patients suffering from endometriosis and adenomyosis

Conditions: Endometriosis; Adenomyosis

Summary: endometriosis and adenomyosis are chronic difficult diseases affecting a significant proportion of reproductive age women. it is hoped that the investigators can collect the health profile of these participants using structured questionnaires on their quality of life, reproductive health, collect the sonographic characteristics, identify the risks factors of participants suffering from severe disease, and to propose the best treatment modality for different patient groups, both with and without fertility wish.

endometriosis and adenomyosis are chronic difficult diseases affecting a significant proportion of reproductive age women. not only the disease can lead to chronic pelvic pain, dyspareunia and dysmenorrhea, it is also associated with impaired reproductive health, infertility and tubal-peritoneal disease. adenomyosis can also result in anaemia due to the increased uterine volume and menstrual blood loss. different treatment options are available for this group of participants, ranging from simple medical treatment to control symptoms, such as analgesics for pain control, transexemic acid to reduce menstrual blood loss, to hormonal treatment and the more radical surgical treatment. as a tertiary gynaecology referral centre, the investigators encounter a large volume of patients suffering from endometriosis and adenomyosis of different disease severity. through this prospective observational study, it is hoped that the investigators can collect the health profile of participants using structured questionnaires on their quality of life, reproductive health, collect the sonographic characteristics, identify the risks factors of patients suffering from severe disease, and to propose the best treatment modality for different participant groups, both with and without fertility wish. patients attending the pelvic mass clinic/ endometriosis clinic with the histologically confirmed or sonographic evidence of endometriosis/ adenomyosis will be invited to participate in the prospective study. their demographic data will be collected. symptomatology and health profile will be collected via questionnaires (e.g.ehp-30, sf 36, fsfi) to evaluate the physical, psychological, sexual and social aspects of patients affecting by the disease. menstrual chart with be recorded. physical examination including abdominal and pelvic examination will be performed. pelvic sonography will be offered and recorded systematically. different medical/ surgical treatments will be offered based on patient's clinical condition in an evidence-based approach and clinical guidance. their treatment outcome will be assessed during the follow-up. surgical findings will be recorded and disease severity graded by use of afs scores. pathological findings will be evaluated.

Eligibility criteria:
inclusion criteria: * with endometriosis or adenomyosis confirmed by ultrasound or mri exclusion criteria: * refuse to participate in the study, less than 18 years old, menopausal, illiterate or mentally incapable

Keywords: endometriosis adenomyosis
clinical outcomes of robotic versus laparoscopic distal gastrectomy for gastric cancer

Conditions: Stomach Neoplasm; Robotic Surgery

Summary: the purpose of this study is to explore the clinical outcomes of the robotic distal gastrectomy for patients with gastric adenocarcinoma（ct1-4a, n-/+, m0）.

robotic surgery has been developed with the aim of improving surgical quality and overcoming the limitations of conventional laparoscopy in the performance of complex mini-invasive procedures. the study is designed to explore the clinical outcomes of the robotic distal gastrectomy by comparing short- and long-term outcomes including financial cost of robotic and laparoscopic distal gastrectomy in the treatment of gastric adenocarcinoma （ct1-4a, n-/+, m0）.

Eligibility criteria:
inclusion criteria: 1. age from over 18 to under 75 years 2. primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy 3. ct1-4a(clinical stage tumor), n-/+, m0 at preoperative evaluation according to the american joint committee on cancer (ajcc) cancer staging manual 8th edition 4. expected to perform distal gastrectomy with d1+/d2 lymph node dissction to obtain r0 resection sugicall results. 5. performance status of 0 or 1 on ecog (eastern cooperative oncology group) scale 6. asa (american society of anesthesiology) class i to iii 7. written informed consent exclusion criteria: 1. women during pregnancy or breast-feeding 2. severe mental disorder 3. history of previous upper abdominal surgery (except laparoscopic cholecystectomy) 4. history of previous gastric surgery (except esd/emr (endoscopic submucosal dissection/endoscopic mucosal resection )for gastric cancer) 5. gastric multiple primary carcinoma 6. enlarged or bulky regional lymph node （diameter over 3cm）supported by preoperative imaging 7. history of other malignant disease within the past 5 years 8. history of previous neoadjuvant chemotherapy or radiotherapy 9. history of unstable angina or myocardial infarction within the past 6 months 10. history of cerebrovascular accident within the past 6 months 11. history of continuous systematic administration of corticosteroids within 1 month 12. requirement of simultaneous surgery for other disease 13. emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer 14. fev1\<50% of the predicted values

Keywords: stomach neoplasm robotic surgery distal gastrectomy
effect of neonatal care education for primiparous pregnant women on postpartum maternal function and quality of life

Conditions: Life Quality; Functional Status

Summary: this study aimed to evaluate the effect of neonatal care education for primiparous pregnant women on postpartum maternal function and quality of life.

this was a single blind randomised controlled experimental study. the sample size of the study was calculated using the g\*power 3.1.7 program, considering a 5% margin of error and 95% confidence interval, and was determined to be at least 61. therefore, the sample was planned to consist of 122 pregnant women, including 61 pregnant women in the intervention group and 61 pregnant women in the control group. study inclusion criteria being at least a primary school graduate. being a primiparous pregnant woman. being able to provide feedback. study exclusion criteria being a multiparous pregnant woman. being a high-risk pregnant woman. participants who met the study inclusion criteria were provided with information about the purpose and conduct of the study, and their consent to participate was then obtained. the interviews were conducted in the breastfeeding room at the uşak dikilitaş family health centre. the data were collected between november 2022 and november 2023. the family health centre has two vaccination rooms, two antenatal care rooms, two observation rooms, and two breastfeeding rooms. each pregnant woman was individually enrolled in an education session held in the breastfeeding room. the breastfeeding room was approximately 20 m², which was considered standard for accommodating training for an average of three pregnant women. the breastfeeding room was quiet, had a suitable temperature, and was located on the first floor in the middle of the corridor.

Eligibility criteria:
inclusion criteria: * being at least a primary school graduate. * being a primiparous pregnant woman. * being able to provide feedback. exclusion criteria: * being a multiparous pregnant woman. * being a high-risk pregnant woman.

Keywords: functional status life quality mothers pregnancy
ankylosing spondylitis and antiphospholipid antibodies

Conditions: Ankylosing Spondylarthritis

Summary: the main objective is to evaluate the prevalence of anti-phospholipid antibodies (apla) in patients with ankylosing spondylitis (as). the secondary objectives are: (1) to determine whether the presence of these antibodies is symptomatic (thrombosis or not); (2) identify a possible relationship between the presence of apla and a particular form of sa (axial or peripheral); (3) to determine whether the presence of apla is more frequent in patients receiving anti-tumor necrosis factor (tnf) alpha therapy.

methods: experimental design: longitudinal study prospective in a single center. the ankylosing spondylitis assesment study (asas) criteria are: (1) age \<45 years, back pain ≥ 3 months, sacroiliitis on imaging and ≥ 1 associated minor criterion, or (2) hla b27 positive and ≥ 2 minor criteria. minor criteria are: inflammatory back pain, arthritis, enthesitis, uveitis, dactylitis, psoriasis, crohn's disease, good clinical response to nsaids, family history of human leukocyte antigen hla b27 and inflammatory syndrome. plan investigation: patients in the study will be seen first in consultation to gather the necessary information: history taking (including venous and arterial embolic events and obstetric history), the usual treatment, asas criteria of therapeutic as, current and previous, comprehensive physical examination. apla will be measured at baseline and at least 3 months if initially positive. outcome: the primary endpoint is the presence or absence of apla: anti-cardiolipin antibodies (cla) immunoglobulin m (igm) or immunoglobulin g (igg), circulating anticoagulant lupus (cca), anti-beta2 glycoprotéine1 antibodies (β2gp1a) igm or igg. the secondary endpoints are: * the presence of thrombosis (past or present) or obstetrical accident (anterior) * relationship between the presence of apla and a particular form of as (axial or peripheral) * relationship between the presence of apla and anti-tnf alpha therapy calendar: the expected study duration is 16 months. statistical analysis plan a descriptive analysis will be performed. the variables are described by their number and percentage; quantitative variables are described by their mean and standard deviation. a calculation of the prevalence of apla will be made. univariate analysis will be performed for the secondary objectives by the chi 2 test or fisher exact test according to the application conditions.

Eligibility criteria:
inclusion criteria patients : * older than 18 years * with sa according to asas criteria * followed in the internal medicine department of the reims university hospital * who have given their consent * affiliated to social security insurance exclusion criteria patients : * minor patients * patients with autoimmune disease (except the inflammatory bowel disease) * cancer * coagulation disorders * anticoagulant treatment (anticoagulation out for events history thrombus embolism) * pregnant women * patients protected by law
study to evaluate effectiveness and tolerability of oros hydromorphone for cancer pain treatment in korean patients

Conditions: Cancer Pain

Summary: the purpose of this study is to evaluate the effectiveness and tolerability of once-daily oros ("osmotic release oral system" \[a controlled release oral medication delivery system in the form of a tablet\]) hydromorphone for cancer pain treatment in korean cancer patients.

this is a prospective (expected to happen), open-label (type of clinical study in which both the researchers and participants know which treatment is being administered), multicenter (conducted at multiple centers), single-arm (only one group), study to evaluate the effectiveness and tolerability (capable to tolerate) of once-daily oros hydromorphone for cancer pain treatment. this is a 14-week study consisting of 2-week efficacy evaluation period (1st evaluation on day 1 and 2nd evaluation on days 15±2) and a 12-week extension phase. 99 patients will receive once-daily oros hydromorphone for 2 weeks .after 2 weeks, if a patient has continuous cancer pain and the investigator deems it necessary to administer the same medicine as the study medication then the patient may participate voluntarily in the 12 weeks extension phase. at the extension phase, other continuous-type strong opioid analgesics (painkiller) may be administered at the same time for the adjustment of cancer pain based on the discretion of the investigator.

Eligibility criteria:
inclusion criteria: * cancer pain and require opioid analgesics * average pain intensity measured at the baseline (patient's medical status before any treatment or research is done) for the past 24 hours over numeric rating scale (nrs) is 4 * never taken continuous-type strong opioid analgesics * must be post-menopausal or if pre-menopausal, must use an acceptable method of birth control exclusion criteria: * acute digestion related disease, such as dysphagia (difficulty in swallowing), vomiting, no enterokinesia (movements of intestine), intestinal obstruction, acute intestinal stricture (narrowing of a passageway) * expected to undergo radioactive treatment (radiation therapy) between day 1 and day 15 of study * being administered with monoamine oxidase inhibitor (eg, moclobemide, selegiline, toloxatone, etc) or within 2 weeks of administration thereof

Keywords: cancer pain oros osmotic release oral system hydromorphone painkiller opioid analgesic korean patients
cgrp-induced migraine attacks in patients who have tried anti-cgrp monoclonal antibody treatment

Conditions: Migraine

Summary: the investigators aim to investigate the incidence of migraine attacks after calcitonin gene-related peptide (cgrp) infusion in patients who have tried anti-cgrp monoclonal antibody treatment for the prevention of migraine.

calcitonin gene-related peptide (cgrp) plays a role in migraine pathophysiology. infusions of cgrp can trigger migraine-like attacks in migraine patients and antibodies against cgrp or the cgrp receptor significantly reduces the number of migraine days per month when administered regularly. some patients however, do not experience migraine attack after cgrp infusion, and some do not experience migraine reduction with antibodies. the underlying mechanisms of these effects are largely unknown. the purpose of this study is to examine cgrp-induced migraine in patients who have evaluated the efficacy of anti-cgrp monoclonal antibody treatment for migraine using a purpose-developed standardized interview. the investigators will use a double-blind, placebo-controlled crossover study design to examine migraine susceptibility to cgrp in these patients.

Eligibility criteria:
inclusion criteria: * diagnosis of migraine according to the international classification of headache disorders version 3-beta * subject has tried anti-cgrp antibodies for migraine * women of childbearing potential are on safe contraception exclusion criteria: * women of childbearing potential who do not use contraception. includes non-hysterectomized women who have not been menopausal for at least two years. safe contraception includes condoms, intrauterine devices, p-pills, surgical sterilization or gestagen injections. * daily drug intake apart from contraceptives and preventive medication for migraine. * ingestion of any drug 4 half-lifes before study start apart from contraceptives. * pregnant or breast-feeding women * migraine on the study day or less than 48 hours before cgrp infusion. * a history of cardiovascular and/or cerebrovascular disease * systolic blood pressure \>150 mmhg and/or diastolic blood pressure \> 100 mmhg on study day. * systolic blood pressure \<90 mmhg and/or diastolic blood pressure \< 50 mmhg on study day. * a history of mental illness * a history of any illness or condition that is deemed relevant for participation by the investigator.

Keywords: calcitonin gene-related peptide
effect of breast implants om mammography screening

Conditions: Breast Cancer

Summary: the purpose of the study is to survey how many women have breast implants in the mammography screening population and the effect of implants on the number and type of examinations and on costs.


Eligibility criteria:
inclusion criteria: * women participating in the mammography screening program. exclusion criteria: * none

Keywords: breast cancer plastic surgery breast implant mammography screening health economy
seretide 100/50 bd (twice daily) versus flixotide 100 bd as initial maintenance therapy in moderate asthma in adults

Conditions: Asthma

Summary: this study will compare during 12 weeks, two treatment strategies for initial maintenance therapy : fluticasone propionate alone or the salmeterol/fluticasone propionate combination in adults with moderate persistent asthma

a multicentre randomised, double-blind, parallel-group study to compare the salmeterol/fluticasone propionate combination (seretidetm diskustm 50/100) 50/100µg one inhalation twice daily with fluticasone propionate (flixotidetm diskustm 100) 100µg one inhalation twice daily as initial maintenance therapy for 12 weeks in adults with persistent moderate asthma

Eligibility criteria:
inclusion criteria: * male or female ≥ 18 * documented history of asthma * reversibility fev1 or pef ≥ 12% (post 400µg salbu) * moderate asthma (daily symptoms, daily rescue use, pef = 60-80% predicted value) * naive or ≥ 4weeks-free ics (inhaled corticosteroids) exclusion criteria: * respiratory disorder * fev1\<60% predicted * exacerbation/respiratory infection ≤ 4 weeks * oral/parenteral/depot corticosteroids ≤ 6 months * laba/oral β2 agonist/ alt/ theophylline ≤ 4 weeks * smoker or former smoker ≥ 5 packs year

Keywords: persistent moderate asthma adults initial maintenance therapy
safety and efficacy of bmmncin patients with mental retardation

Conditions: Mental Retardation

Summary: mental retardation is a condition diagnosed before age 18 that includes below-average general intellectual function, and a lack of the skills necessary for daily living. mental retardation affects about 1 - 3% of the population. there are many causes of mental retardation, but find a specific reason in only 25% of cases.bone marrow derived stem cells are used in this condition to prove its safety and efficacy .


Eligibility criteria:
inclusion criteria: * age limit: 5 -50 * primary diagnosis of mental retardation (iq \< 70) * willingness to undergo autologous bone marrow derived mono nuclear stem cell (bmmncs) transplantation. * to give an informed consent as well as sign the required informed consent form (icf)/video consent for the study. * willingness to regularly visit the hospital / clinic for follow up during the follow up period / on prior agreed time points as per the protocol. exclusion criteria: * positive test results for hiv and aids complex ,hcv (hepatitis c virus ), hbsag and syphilis * advanced age that may produce deteriorating cognitive or motor functioning * multiple sensory or motor disabilities that will interfere with seeing the stimuli and responding to the computer * poor general health

Keywords: mental retardation , stem cell,bmmnc
evaluation of multidisciplinary palliative care on terminal cancer patients in taiwan

Conditions: Cancer

Summary: the purpose of the study is to compare the quality of dying and death of terminal cancer patients from the perspectives of medical staff and main care giver (family). the hypothesis is that their view points will be different.


Eligibility criteria:
inclusion criteria: * cognitively intact. * contact with the patient in the last month. exclusion criteria: * cognitively not intact. * no contact with the patient in the last month.

Keywords: quality of dying and death of terminal cancer patients
a study evaluating the use of an indoor air quality monitor to promote a smoke-free home

Conditions: Smoking; Smoking Cessation; Smoking Reduction; Smoking Habit; Smoking Behaviors; Smoking, Tobacco; Smoking, Cigarette; Smoking (Tobacco) Addiction; Tobacco Use; Tobacco Smoking

Summary: the purpose of this study is to evaluate how using an indoor air quality monitor can promote a smoke-free home for cancer patients who are enrolled in msk's tobacco treatment program.


Eligibility criteria:
inclusion criteria: * adult (aged \>18 years) msk patients as per the ehr * has been referred and enrolled in the msk ttp and completed the initial counseling session as per the ttp clinical database * reports current (within the past 30 days) tobacco use (i.e., cigarettes and/or any other tobacco products) as per the ttp intake form * must be english-speaking in the ehr * must be reachable by phone as per self-report * must have wi-fi available at home as per self-report exclusion criteria: * patient reports that no smoking is allowed, by them or anyone else, in the home as per the ttp intake form and/or per self-report

Keywords: smoking smoking cessation smoking reduction smoking habit smoking behaviors smoking, tobacco smoking, cigarette smoking (tobacco) addiction tobacco use tobacco smoking air quality indoor air quality monitoring devices 24-260 memorial sloan kettering cancer center
physiotherapist led group-exercise compared physical activity on prescription, a 3 months follow-up

Conditions: Atrial Fibrillation

Summary: to investigate the effect of exercise or pap prescription 3 months after completion of the study "should elderly patients with atrial fibrillation be offered physiotherapist group exercise or can physical activity on prescription (pap) be used as an alternative?" regarding level of physical fitness, physical activity, heart rate and health related quality of life (hr-qol). also if any of the investigated variables can predict the possible change in physical fitness.

patients who have completed study will be offered a follow-up after 3 months regarding physical fitness, physical activity, heart rate and hr-qol. physical fitness will be measured by a symptom limited bicycle test and a muscle endurance test. physical activity will be measured by accelerometer and the international physical activity questionnaire (ipaq) and a physical activity diary, hr-qol will be measured by short form (sf-36).

Eligibility criteria:
inclusion criteria: * completed the study "should elderly patients with atrial fibrillation be offered physiotherapist group exercise or can physical activity on prescription (pap) be used as an alternative?" exclusion criteria: * not completed the above study or denied participation in follow up

Keywords: follow up exercise rehabilitation
neurobehavioral responses to multisensory stimulation module in preterm neonates

Conditions: Preterm Neonates

Summary: preterm neonates who receive multi-sensory stimulation exhibit more neurobehavioral development than those who don't.

this study will be conducted at neonatal intensive care unit (nicu) of alexandria university children's hospital (auch) at smouha, alexandria, egypt. a sample of 60 preterm neonates.the study subjects will be randomly assigned into two equal groups (control and multi-sensory stimulation groups) using random number table. each group will be comprised of 30 neonates. the first neonate will be assigned to the control group and the second neonate will be assigned to the multi-sensory stimulation group. control group: preterm neonates will receive only routine care of the unit. multi-sensory stimulation group: preterm neonates will receive multi-sensory stimulation intervention beside routine care of the unit.

Eligibility criteria:
inclusion criteria: * gestational age ranges from 32 and 36 weeks. * the preterm infant's 5 min apgar is 6 and more. exclusion criteria: * history of cardiopulmonary resuscitation or surgery. * history of intraventricular hemorrhage grade ii and above. * major congenital malformations

Keywords: multisensory stimulation module neurobehavioral responses neonates